Compare RIGL & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
| Metric | RIGL | IRS |
|---|---|---|
| Founded | 1996 | 1943 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 990.7M |
| IPO Year | 2000 | 1998 |
| Metric | RIGL | IRS |
|---|---|---|
| Price | $39.76 | $10.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $64.40 | $21.87 |
| AVG Volume (30 Days) | 204.0K | ★ 271.7K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 13.59% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $5.32 | N/A |
| Revenue Next Year | $24.14 | $7.14 |
| P/E Ratio | $21.00 | ★ $3.66 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $10.85 |
| 52 Week High | $52.61 | $19.14 |
| Indicator | RIGL | IRS |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 27.45 |
| Support Level | $37.60 | N/A |
| Resistance Level | $43.74 | $16.10 |
| Average True Range (ATR) | 2.72 | 0.61 |
| MACD | -0.62 | -0.17 |
| Stochastic Oscillator | 15.98 | 6.90 |
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
IRSA Inversiones y Representaciones SA is a real estate company. Its segments are Shopping Malls which includes the operating results from its portfolio of shopping malls principally comprising lease and service revenue from tenants; Offices segment includes the operating results from lease revenue of offices; Hotels segment includes the operating results of its hotels mainly comprised of room, catering and restaurant revenue; Sales and Developments segment includes the results generated by other rental properties, the development, maintenance and sales of undeveloped parcels of land and/or trading properties; and Others segment includes the entertainment activities. Majority of revenue comes from Shopping Malls segment.